(Q44193648)

30 November 2017

Identification of glutathione conjugates of troglitazone in human hepatocytes (English)

1 reference

30 November 2017

7

1 reference

30 November 2017

Saileta Prabhu

1

1 reference

30 November 2017

Andrew Fackett

2

1 reference

30 November 2017

Scott Lloyd

3

1 reference

30 November 2017

Holly A McClellan

4

1 reference

30 November 2017

Chris M Terrell

5

1 reference

30 November 2017

Paul M Silber

6

1 reference

30 November 2017

1 November 2002

1 reference

Chemico-biological Interactions

30 November 2017

1 reference

30 November 2017

142

1 reference

30 November 2017

1-2

1 reference

30 November 2017

83-97

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

30 November 2017

1 reference

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Clinical pharmacokinetics of troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Effect of troglitazone on steady-state pharmacokinetics of digoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Lessons from the glitazones: a story of drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Toxic effect of troglitazone on cultured rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

Rosiglitazone and liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-2797%2802%2900056-X

10.1016/S0009-2797(02)00056-X

7 January 2021

Identifiers

DOI

1 reference

release_pd7ix3lg2vefzoyqkbdevnjcae

30 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pd7ix3lg2vefzoyqkbdevnjcae

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference